PREVENT

Phase 3Biologic

UUniversity of Utah

PREVENT is one of 4 biologic programs targeting HPV Vaccination. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV VaccinationActive, not recruiting

HPV VaccinationPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in HPV Vaccination

#DrugCompanyPhaseTrials

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

2 2

HAV Vaccine

Takeda

Phase 3

1 3

Bivalent HPV Vaccine

ZZagazig University

Phase 3

1 4

PREVENT

UUniversity of Utah

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

HPV Vaccination

NCT07217145

Clinical

Trials by Indication[1]

HPV Vaccination1 trial

PREVENT: Practice-based Approaches to Promote HPV Vaccination in the Safety Net - Randomized Controlled Trial (RCT)

Active, not recruiting·UUniversity of Utah·Phase 3·NCT07217145·1,455 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PREVENT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PREVENT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PREVENT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Utah

PREVENT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

HPV Vaccination1 trial

References

Drug Info

Quick Facts

Related News